| Characterization of HIV-infectedpatients |
Anti-HAV ≥ 20mIU/mL (n=23) |
Anti-HAV <20mIU/mL (n=6) |
p |
Median age at study inclusion (years)
(range) |
12.4
(9.7, 16.8) |
13.5
(10.9 , 16.2) |
0.450* |
| Median age at primary HAV immunization (years) (range) |
5.13
(1.92, 9.32) |
6.01
(3.18, 8.96) |
0.628* |
Median age at beginning of ARV
(years) (range) |
1.73
(0.27,5.63) |
3.18
(1.67, 4.34) |
0.196* |
Female
(%) |
11
(47.8) |
3
(50) |
0.924† |
Z score H/A
(range) |
- 0.88
(-2.21, + 1.06) |
- 0.40
(-1.51, +1.44) |
0.205* |
Z score BMI
(range) |
- 0.10
(-2.6, +1.7) |
- 0.36
(-2.64, +0.89) |
0.726* |
Clinical category
N/A/B (%)
C (%) |
20 (87.0)
3 (13.0) |
5 (83.3)
1 (16.7) |
0.819†
0.119† |
Immunologic category
1/2 (%)
3 (%) |
21(91.3)
2 (8.7) |
4 (66.7)
2 (33.3) |
Median CD4+ T cells before starting ART
(range) |
1532
(315, 4245) |
720
(520, 1580) |
0.058* |
Median nadir CD4+ T cells count (cells/mm3)
(range) |
485
(140, 1179) |
200
(5, 559) |
0.019* |
Median currentlog VL (copies/mL)
(range) |
3.0
(1.0, 4.97) |
4.0
(2.16, 5.7) |
0.067* |
Median log VL before starting ART
(range) |
5.2
(4.1 , 7.1) |
4.9
(3.3, 5.2) |
0.216* |
| Number of patients with undetectable current VL (%) |
6/23 (26) |
0/6 (0) |
0.160† |
Number of patients starting ART aged ≤ 1 year (%)
Number of patients without ART at primary immunization (%) |
8/23 (34.7)
0/23 (0) |
0/6 (0)
1/6 (16.6) |
0.089†
0,207† |
| Number of patients without ART at the current study (%) |
4/23 (17.4) |
3/6 (50.0) |
0.096† |
* Mann Whitney test, † Fisher’s exact test; ART: Antiretroviral therapy; VL: HIV viral load |
